Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant
Open Access
- 18 August 1999
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 18 (33) , 4699-4709
- https://doi.org/10.1038/sj.onc.1202841
Abstract
The tumour suppressor p53 plays a complex role in the regulation of apoptosis. High levels of wild type p53 potentiate the apoptotic response, while physiological range, low levels of the protein have an anti-apoptotic activity in serum starved immortalized fibroblasts. Here we report that primary fibroblast-like cells that show normal growth control are also efficiently protected from apoptosis by the endogenous p53 activity. The capacity to inhibit apoptosis is not restricted to the wild type protein: the R→H175 p53 mutant fully retains the anti-apoptotic activity of the wild type p53, providing a possible explanation for its high oncogenicity. Using a series of point and deletion mutants of p53 under the control of tetracycline-regulated promoter we show that certain mutants, like the wild type, protect cells at low levels but lead to apoptosis when overexpressed. This latter effect is lost upon deletion of a proline-rich domain in the NH2 part of the protein. The anti-apoptotic activity can be mapped to the extreme carboxy-terminal part of the protein and is therefore independent of other well characterized p53 activities. Our results add a new level of complexity to the network of interactions mediated by p53 in normal physiology and pathology.Keywords
This publication has 60 references indexed in Scilit:
- Transgenic mice with p53-responsive lacZ: p53activity varies dramatically during normal development and determines radiation and drug sensitivity invivoThe EMBO Journal, 1997
- Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4aCell, 1997
- Regulation of Mutant p53 Temperature-sensitive DNA BindingPublished by Elsevier ,1996
- Tissue-specific inactivation of p53 tumor suppression in the mouse.Genes & Development, 1996
- Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting ProteinsJournal of Biological Chemistry, 1996
- Allosteric activation of latent p53 tetramersCurrent Biology, 1994
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumorsCell, 1993
- Regulation of the specific DNA binding function of p53Cell, 1992
- In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenesCell, 1986